Dr. Takimoto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1490 O'Brien Drive
Suite A
Menlo Park, CA 94025Phone+1 650-352-4132- Is this information wrong?
Education & Training
- UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineFellowship, Clincal Pharmacology and Therapeutics, 1994 - 1996
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- University of California (San Francisco)Residency, Internal Medicine, 1986 - 1989
- Yale School of MedicineClass of 1986
Certifications & Licensure
- CA State Medical License 1987 - 2025
- TX State Medical License 2000 - 2024
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer Start of enrollment: 2016 Nov 02
Publications & Presentations
PubMed
- 112 citationsA Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid MalignanciesSanjay Goel, Alain C. Mita, Monica M. Mita, Eric K. Rowinsky, Quincy Siu-Chung Chu
Clinical Cancer Research. 2009-06-15 - 328 citationsFirst-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, Sumit A. Shah, Sreenivasa R Chandana
Journal of Clinical Oncology. 2016-05-20 - 910 citationsExpression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Shirin Khambata-Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher T. Harbison
Journal of Clinical Oncology. 2007-08-01
Abstracts/Posters
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b ResultsChris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human PrimatesChris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Call TranscriptApril 6th, 2023
- Chutes & Ladders—Scholar Rock Founding CEO Returns to Top Spot as Kingsley Swiftly ExitsAugust 6th, 2021
- Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s LymphomaJune 15th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: